Genentech and Biogen Idec filed a declatory relief complaint in US District court on March 23rd following the issue of US Patent 7,682,612. The complaint names GenMab partner GSK as infringing due to the latter's sale of Arzerra (ofatumumab) in the United States for the treatment of certain CLL patients.
The Genentech and Biogen Idec patent contains a claim to a method for treating CLL with anti-CD 20 antibodies where the method does not comprise treatment with radiolabelled antibodies.
Arzerra is an anti-CD 20 antibody and was approved for sale in October 2009 under the FDAs accelerated approval process. The process is meant to speed approval for drugs that treat disease classes where there are unmet medical needs.
GenMab and GSK indicate that they will need to analyze the claims under the complaint before issuing any response.
Posted by Bruce Lehr March 28, 2010